Literature DB >> 15370587

Arthrodesis for tuberculous coxarthritis: good outcome in 32 adolescents.

H Mustafa OZdemir1, Ugur Yensel, Tunç Cevat Ogün, Hakan Senaran, Abdurrahman Kutlu.   

Abstract

BACKGROUND: There is no consensus on best treatment of advanced tuberculous coxarthritis in young patients. PATIENTS AND METHODS: We report our results concerning hip arthrodesis for advanced tuberculous arthritis of the hip in 32 adolescents. The operation was preceded by standard antituberculous chemotherapy for 4 weeks, which was continued for 12 months after surgery. At the last follow-up, clinical and radiographic examinations of the ipsilateral knee, contralateral hip and lower back were done. We evaluated function, limitations, and presence of pain with our usual questions.
RESULTS: Their average age at the time of operation was 16 (12-18) years and the average duration of followup 12 (10-18) years. Solid bony fusion occurred in all patients after mean 5 months and no complications developed in the postoperative period. 28 patients were satisfied with the fused hip. No patients had reactivation of tuberculosis in any part of their body. The results were comparable to those of arthrodesis performed for other causes.
INTERPRETATION: Hip arthrodesis is an alternative method of treatment for advanced stages of tuberculous coxarthritis in the adolescent. Copyright 2004 Taylor & Francis

Entities:  

Mesh:

Year:  2004        PMID: 15370587

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  2 in total

1.  Two-stage treatment of acetabular bone defect in tuberculosis of the hip by intended ankylosis followed by total hip arthroplasty: a case report.

Authors:  Els E Vogelpoel; Jurjen J Been; Arthur A de Gast
Journal:  Cases J       Date:  2009-03-25

2.  Application of the Ilizarov technique for knee joint arthrodesis as a treatment for end-stage tuberculosis of the knee.

Authors:  Jiachen Sun; Qiang Li; Feng Gao; Zhou Xiang; Qi Huang; Lang Li
Journal:  BMC Musculoskelet Disord       Date:  2020-08-26       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.